Dr. Sofie Demasure, oncoloog: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Dr. Sofie Demasure, oncoloog
Largest movements
- Cash +€290,457
up €290,457 (+140.3%), from €207,010 to €497,467
mainly Net result for the year (+€426,796) and Smaller working-capital items (+€1,562)
- Current investments +€59,113
up €59,113 (+171.4%), from €34,483 to €93,596
- Deferred charges and accrued income +€40,187
up €40,187 (+22.8%), from €176,014 to €216,201
- Financial fixed assets +€40,000
up €40,000 (+400.0%), from €10,000 to €50,000
- Reserves +€426,796
up €426,796 (+115.1%), from €370,651 to €797,446
- Gross operating margin +€243,117
up €243,117 (+77.1%), from €315,142 to €558,260
- Taxes +€40,265
up €40,265 (+42.0%), from €95,972 to €136,237
- Financial income +€7,270
up €7,270 (+2819.2%), from €258 to €7,528
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €427,507 | €857,265 | +€429,757 | +100.5% |
| Fixed assets | 21/28 | €10,000 | €50,000 | +€40,000 | +400.0% |
| Financial fixed assets | 28 | €10,000 | €50,000 | +€40,000 | +400.0% |
| Current assets | 29/58 | €417,507 | €807,265 | +€389,757 | +93.4% |
| Current investments | 50/53 | €34,483 | €93,596 | +€59,113 | +171.4% |
| Cash at bank and in hand | 54/58 | €207,010 | €497,467 | +€290,457 | +140.3% |
| Deferred charges and accrued income | 490/1 | €176,014 | €216,201 | +€40,187 | +22.8% |
| Total equity and liabilities | 10/49 | €427,507 | €857,265 | +€429,757 | +100.5% |
| Equity | 10/15 | €373,651 | €800,446 | +€426,796 | +114.2% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Reserves | 13 | €370,651 | €797,446 | +€426,796 | +115.1% |
| Distributable reserves | 133 | €370,651 | €797,446 | +€426,796 | +115.1% |
| Amounts payable | 17/49 | €53,857 | €56,819 | +€2,962 | +5.5% |
| Amounts payable within one year | 42/48 | €53,857 | €56,351 | +€2,494 | +4.6% |
| Trade debts | 44 | - | €566 | +€566 | |
| Suppliers | 440/4 | - | €566 | +€566 | |
| Taxes, remuneration and social security | 45 | €53,434 | €54,834 | +€1,400 | +2.6% |
| Taxes | 450/3 | €53,434 | €54,834 | +€1,400 | +2.6% |
| Other amounts payable | 47/48 | €423 | €951 | +€528 | +124.9% |
| Accrued charges and deferred income | 492/3 | - | €468 | +€468 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €0 | - | = | |
| Other operating charges | 640/8 | €190 | €593 | +€404 | +212.7% |
| Gross operating margin | 9900 | €315,142 | €558,260 | +€243,117 | +77.1% |
| Operating profit (loss) | 9901 | €314,952 | €557,666 | +€242,714 | +77.1% |
| Financial income | 75/76B | €258 | €7,528 | +€7,270 | +2819.2% |
| Recurring financial income | 75 | €258 | €7,528 | +€7,270 | +2819.2% |
| Financial charges | 65/66B | €1,735 | €2,161 | +€426 | +24.6% |
| Recurring financial charges | 65 | €1,735 | €2,161 | +€426 | +24.6% |
| Profit (loss) for the period before taxes | 9903 | €313,475 | €563,033 | +€249,557 | +79.6% |
| Income taxes | 67/77 | €95,972 | €136,237 | +€40,265 | +42.0% |
| Profit (loss) for the period | 9904 | €217,503 | €426,796 | +€209,292 | +96.2% |
| Profit (loss) for the period to be appropriated | 9905 | €217,503 | €426,796 | +€209,292 | +96.2% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 11 October 2026 via checked.be.